Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder

被引:22
|
作者
Evans, Elizabeth A. [1 ]
Yoo, Caroline [2 ]
Huang, David [2 ]
Saxon, Andrew J. [3 ]
Hser, Yih-Ing [2 ]
机构
[1] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Hlth Promot & Policy, 312 Arnold House,715 North Pleasant St, Amherst, MA 01003 USA
[2] Univ Calif Los Angeles, Integrated Subst Abuse Programs, Semel Inst Neurosci & Human Behav, 11075 Santa Monica Blvd,Ste 200, Los Angeles, CA 90024 USA
[3] Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA
关键词
Buprenorphine; Treatment acceptability; access; and utilization; Opioid use disorder; Pharmacotherapy; Longitudinal; MAINTENANCE TREATMENT; PATIENT PERSPECTIVES; METHADONE TREATMENT; ADDICTION; DEPENDENCE; RETENTION; OUTCOMES; MORTALITY; ABUSE; FACILITIES;
D O I
10.1016/j.jsat.2019.08.002
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Nationwide efforts seek to address the opioid epidemic by increasing access to medications for opioid use disorder (OUD), particularly with buprenorphine. A poorly understood challenge is that among individuals with OUD who do receive buprenorphine, many do not adhere to the pharmacotherapy long enough to achieve sustained benefits. We aimed to identify factors associated with buprenorphine treatment utilization over time. Methods: We used random-intercept modeling to identify factors associated with buprenorphine treatment utilization over 2 years after first follow-up by 789 individuals with OUD who had participated in a multi-site randomized clinical trial of buprenorphine compared to methadone. Key predictors were participants' reports of buprenorphine treatment accessibility and acceptability (assessed at first follow-up) and their interaction effects, controlling for baseline randomization status, sociodemographics, and other covariates. Results: Approximately 9.3-11.2% of participants utilized buprenorphine treatment over the 2 years of follow-up. Interaction effects indicated that individuals who perceived buprenorphine to be both accessible and acceptable were most likely to use buprenorphine during follow-up, controlling for other factors. In contrast, individuals who perceived buprenorphine to be unacceptable were least likely to use buprenorphine, regardless the level of perceived access to the medication. Buprenorphine treatment utilization was also negatively associated with Hispanic ethnicity, West coast context, and cumulative months receiving methadone treatment and incarceration during follow-up. Conclusions: To engage more individuals with OUD in long-term treatment with buprenorphine, interventions should target buprenorphine treatment acceptability, in addition to increasing buprenorphine access, and tailor efforts to meet the needs of vulnerable populations.
引用
收藏
页码:19 / 28
页数:10
相关论文
共 36 条
  • [21] Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network
    Wu, Li-Tzy
    John, William S.
    Ghitza, Udi E.
    Wahle, Aimee
    Matthews, Abigail G.
    Lewis, Mitra
    Hart, Brett
    Hubbard, Zach
    Bowlby, Lynn A.
    Greenblatt, Lawrence H.
    Mannelli, Paolo
    ADDICTION, 2021, 116 (07) : 1805 - 1816
  • [22] A brief telephone-delivered peer intervention to encourage enrollment in medication for opioid use disorder in individuals surviving an opioid overdose: Results from a randomized pilot trial
    Winhusen, Theresa
    Wilder, Christine
    Kropp, Frankie
    Theobald, Jeff
    Lyons, Michael S.
    Lewis, Daniel
    DRUG AND ALCOHOL DEPENDENCE, 2020, 216
  • [23] Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial
    James S. H. Wong
    Mohammadali Nikoo
    Jean N. Westenberg
    Janet G. Suen
    Jennifer Y. C. Wong
    Reinhard M. Krausz
    Christian G. Schütz
    Marc Vogel
    Jesse A. Sidhu
    Jessica Moe
    Shane Arishenkoff
    Donald Griesdale
    Nickie Mathew
    Pouya Azar
    Addiction Science & Clinical Practice, 16
  • [24] Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial
    Wong, James S. H.
    Nikoo, Mohammadali
    Westenberg, Jean N.
    Suen, Janet G.
    Wong, Jennifer Y. C.
    Krausz, Reinhard M.
    Schutz, Christian G.
    Vogel, Marc
    Sidhu, Jesse A.
    Moe, Jessica
    Arishenkoff, Shane
    Griesdale, Donald
    Mathew, Nickie
    Azar, Pouya
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2021, 16 (01)
  • [25] HIV-Risk Behavior Among Adults with Opioid Use Disorder During 12 Months Following Pre-trial Detention: Results from a Randomized Trial of Methadone Treatment
    Mitchell, M. M.
    Kelly, S. M.
    O'Grady, K. E.
    Jaffe, J. H.
    Mitchell, S. G.
    Schwartz, R. P.
    AIDS AND BEHAVIOR, 2021, 25 (04) : 1247 - 1256
  • [26] HIV-Risk Behavior Among Adults with Opioid Use Disorder During 12 Months Following Pre-trial Detention: Results from a Randomized Trial of Methadone Treatment
    M. M. Mitchell
    S. M. Kelly
    K. E. O’Grady
    J. H. Jaffe
    S. G. Mitchell
    R. P. Schwartz
    AIDS and Behavior, 2021, 25 : 1247 - 1256
  • [27] Care coordination between rural primary care and telemedicine to expand medication treatment for opioid use disorder: Results from a single-arm, multisite feasibility study
    Hser, Yih-Ing
    Mooney, Larissa J.
    Baldwin, Laura-Mae
    Ober, Allison
    Marsch, Lisa A.
    Sherman, Seth
    Matthews, Abigail
    Clingan, Sarah
    Fei, Zhe
    Zhu, Yuhui
    Dopp, Alex
    Curtis, Megan E.
    Osterhage, Katie P.
    Hichborn, Emily G.
    Lin, Chunqing
    Black, Megan
    Calhoun, Stacy
    Holtzer, Caleb C.
    Nesin, Noah
    Bouchard, Denise
    Ledgerwood, Maja
    Gehring, Margaret A.
    Liu, Yanping
    Ha, Neul Ah
    Murphy, Sean M.
    Hanano, Maria
    Saxon, Andrew J.
    JOURNAL OF RURAL HEALTH, 2023, 39 (04): : 780 - 788
  • [28] Sexually transmitted and blood-borne infection risk reduction with methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: Findings from a Canadian pragmatic randomized trial
    Socias, M. Eugenia
    Cui, Zishan
    Le Foll, Bernard
    Lei, Jingxin
    Stewart, Sherry
    Anand, Rohan
    Jutras-Aswad, Didier
    HIV MEDICINE, 2024, 25 (07) : 817 - 825
  • [29] Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial
    Kosten, Thomas
    Aharonovich, Efrat
    Nangia, Narinder
    Zavod, Abigail
    Akerman, Sarah C.
    Lopez-Bresnahan, Maria
    Sullivan, Maria A.
    ADDICTIVE BEHAVIORS, 2020, 111
  • [30] Exploring the Relationship between Adherence to Therapy, Treatment Acceptability, and Clinical Outcomes in Adults with Attention-Deficit/Hyperactivity Disorder: Results from the COMPAS Multicenter Randomized Controlled Trial
    Lopez-Pinar, Carlos
    Rosen, Helena
    Selaskowski, Benjamin
    Staerk, Christian
    Jans, Thomas
    Retz, Wolfgang
    Retz-Junginger, Petra
    Roesler, Michael
    Sobanski, Esther
    Huss, Michael
    Matthies, Swantje
    van Elst, Ludger Tebartz
    Berger, Mathias
    Jacob, Christian
    Kis, Bernhard
    Colla, Michael
    Alm, Barbara
    Abdel-Hamid, Mona
    Martinez-Sanchis, Sonia
    Carbonell-Vaya, Enrique
    Lux, Silke
    Philipsen, Alexandra
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2024, 93 (01) : 46 - 64